eFFECTOR Therapeutics (EFTRW) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsShort InterestTrendsBuy This Stock EFTRW vs. ATNFW, LBPSW, AEHAW, AIMDW, ALVOW, ARAV, ACABW, BFRIW, BTMDW, and BCTXWShould you be buying eFFECTOR Therapeutics stock or one of its competitors? The main competitors of eFFECTOR Therapeutics include 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Aesther Healthcare Acquisition (AEHAW), Ainos (AIMDW), Alvotech (ALVOW), Aravive (ARAV), Atlantic Coastal Acquisition Corp. II (ACABW), Biofrontera (BFRIW), biote (BTMDW), and BriaCell Therapeutics (BCTXW). These companies are all part of the "pharmaceutical products" industry. eFFECTOR Therapeutics vs. Its Competitors 180 Life Sciences 4D pharma Aesther Healthcare Acquisition Ainos Alvotech Aravive Atlantic Coastal Acquisition Corp. II Biofrontera biote BriaCell Therapeutics eFFECTOR Therapeutics (NASDAQ:EFTRW) and 180 Life Sciences (NASDAQ:ATNFW) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, media sentiment, earnings, analyst recommendations and dividends. Is EFTRW or ATNFW more profitable? Company Net Margins Return on Equity Return on Assets eFFECTOR TherapeuticsN/A N/A N/A 180 Life Sciences N/A N/A N/A Does the media favor EFTRW or ATNFW? In the previous week, eFFECTOR Therapeutics' average media sentiment score of 0.00 equaled 180 Life Sciences'average media sentiment score. Company Overall Sentiment eFFECTOR Therapeutics Neutral 180 Life Sciences Neutral Which has stronger earnings and valuation, EFTRW or ATNFW? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioeFFECTOR TherapeuticsN/AN/AN/AN/AN/A180 Life SciencesN/AN/AN/AN/AN/A SummaryeFFECTOR Therapeutics and 180 Life Sciences tied by winning 0 of the 0 factors compared between the two stocks. Get eFFECTOR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for EFTRW and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EFTRW vs. The Competition Export to ExcelMetriceFFECTOR TherapeuticsBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$224.82M$5.79B$9.92BDividend YieldN/A3.78%6.71%4.53%P/E RatioN/A43.0176.0826.13Price / SalesN/A5,212.37460.9379.98Price / CashN/A13.1936.9659.04Price / BookN/A87.2111.486.09Net IncomeN/A-$90.99M$3.29B$266.51M eFFECTOR Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EFTRWeFFECTOR TherapeuticsN/AN/AN/AN/A$0.00N/A0.0010ATNFW180 Life SciencesN/A$0.21-10.6%N/A+2,104.5%$0.00N/A0.007Positive NewsGap DownLBPSW4D pharmaN/AN/AN/AN/A$0.00$522K0.00N/AAEHAWAesther Healthcare AcquisitionN/A$0.00flatN/AN/A$0.00N/A0.002AIMDWAinosN/A$0.24-20.0%N/AN/A$0.00$110.87K0.0040Positive NewsGap DownALVOWAlvotechN/A$1.04-8.8%N/A-54.9%$0.00$560.10M0.004Positive NewsGap DownARAVAraviveN/A$0.04flatN/AN/A$0.00$9.14M0.0020High Trading VolumeACABWAtlantic Coastal Acquisition Corp. IIN/A$0.05+29.9%N/AN/A$0.00N/A0.0015Gap UpBFRIWBiofronteraN/A$0.14-8.8%N/AN/A$0.00$39.19M0.0070Positive NewsBTMDWbioteN/A$0.01-15.6%N/A-96.6%$0.00$199.07M0.00N/ABCTXWBriaCell TherapeuticsN/A$0.03+31.0%N/A-86.3%$0.00N/A0.008News CoverageShort Interest ↓Gap Up Related Companies and Tools Related Companies ATNFW Alternatives LBPSW Alternatives AEHAW Alternatives AIMDW Alternatives ALVOW Alternatives ARAV Alternatives ACABW Alternatives BFRIW Alternatives BTMDW Alternatives BCTXW Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EFTRW) was last updated on 9/6/2025 by MarketBeat.com Staff From Our PartnersStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored6-Figure Target for BTC by 2025Crypto ETF records broken – here's what’s next The biggest names in finance have built the infrastructure f...Crypto 101 Media | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredOdd “310F trade” doubles investor’s money in just 3 days?Have you heard of 310F? This unusual trade setup has quietly delivered one of the most consistent profit st...Eagle Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe man running the U.S. dollar… is hoarding goldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding eFFECTOR Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share eFFECTOR Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
